
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is positioned to develop best-in-class therapies for metabolic disorders with its highly differentiated GLP-1/GIP asset VK2735 in both subcutaneous and oral formulations likely to be favored by patients and physicians, and its lead TRβ compound VK2809 expected to excel against competitors in both potency and tolerability. With positive trial outcomes and a strong commercialization strategy, Viking Therapeutics has the potential for significant market share and growth, making it a positive stock pick for investors.
Bears say
Viking Therapeutics is heavily reliant on milestone payments and royalties, making it highly susceptible to delays in reaching development, regulatory, and sales milestones. Additionally, Viking's future success is dependent on its Phase 1 maintenance study and the potential incorporation of a maintenance component into future studies, creating uncertainty and potential for delays and setbacks. The company's single molecule, multi-format approach may provide some competitive advantage, but it is not a guarantee for success in a highly competitive and evolving obesity market.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares